{"prompt": "['16', '4.17', 'TREATMENT ADHERENCE/STUDY COMPLIANCE', '47', '4.18', 'PROTOCOL ADHERENCE', '47', '4.19', 'CONCOMITANT MEDICATIONS', '48', '4.19.1 Allowed Medications', '48', '4.19.2 Prohibited Medications/Treatments', '48', '5.', 'WITHDRAWAL PROCEDURES', '49', '6.', 'RISK BENEFIT', '49', '7.', 'STATISTICAL CONSIDERATIONS', '50', '7.1', 'SUMMARIZATION OF RESULTS', '50', '7.2', 'EVALUATING THE EFFECT OF CLINICAL SITES', '52', '7.3', 'ADVERSE Events', '53', '7.4', 'SAMPLE SIZE', '53', '8.', 'INFORMED CONSENT', '53', '9.', 'INSTITUTIONAL REVIEW BOARD', '54', '10.', 'TERMINATION OF THE INVESTIGATION', '54', '11.', 'ADVERSE EVENTS AND UNANTICIPATED ADVERSE DEVICE EFFECTS', '54', '11.1', 'ADVERSE Events', '54', '11.2', 'ANTICIPATED ADVERSE DEVICE EFFECTS ASSOCIATED WITH PROVANT THERAPY SYSTEM', '56', '11.3', 'UNANTICIPATED ADVERSE DEVICE EFFECT (UADE)', '56', '12.', \"INVESTIGATOR'S FILES/RETENTION OF DOCUMENTS\", '57', '12.1', 'SOURCE DOCUMENTS AND BACKGROUND DATA', '57', '12.2', 'AUDITS AND INSPECTIONS', '57', '13.', 'MONITORING THE STUDY', '58', '14.', 'CONFIDENTIALITY OF TRIAL DOCUMENTS AND SUBJECT RECORDS', '58', '15.', 'PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS', '58', '16.', 'REFERENCES', '59', 'APPENDIX A: TIME AND EVENTS SCHEDULE', '62', 'APPENDIX B: AMERICAN DIABETES ASSOCIATION CRITERIA FOR DIAGNOSIS OF DIABETES', '63', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']['17', 'LIST OF ABBREVIATIONS', 'ABI', 'Ankle Brachial Index', 'AE', 'Adverse Event', 'AGE', 'Advanced Glycation End Products', 'CAN', 'Cardiovascular Neuropathy', 'CBT', 'Cognitive Behavioral Therapy', 'CDC', 'Centers for Disease Control and Prevention', 'CFR', 'Code of Federal Regulations', 'CRA', 'Clinical Research Associate', 'DFU', 'Diabetic Foot Ulcerations', 'DSPN', 'Diabetic Distal Symmetric Peripheral Neuropathy', 'DTR', 'Deep Tendon Reflexes', 'ePRO', 'electronic Patient Reported Outcomes', 'E-STIM', 'Electrical Nerve Stimulation', 'FCC', 'Federal Communication Commission', 'FDA', 'Food & Drug Administration', 'HIV', 'Human Immunodeficiency Virus', 'IENFD', 'Intraepidermal Nerve Fiber Density', 'IRB', 'Institutional Review Board', 'ITT', 'Intent to Treat', 'LCD', 'Liquid Crystal Display', 'LOPS', 'Loss of the Protective Sensation', 'LSA', 'Laser Sensor Assembly', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'NCS', 'Nerve Conduction Studies', 'NeuroQoL', 'Neuropathy and foot ulcer specific quality of life instrument', 'NOS', 'Nitric Oxide Synthase', 'NPRS', 'Numeric Pain Rating Scale', 'PAD', 'Peripheral Arterial Disease', 'PEMF', 'Pulsed Electromagnetic Field', 'PGI', 'Patient Global Impression', 'PRFE', 'Pulsed Radio Frequency Energy', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}